Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

A process for determining whether a chemical compound specifically binds to and activates a Y5 receptor which comprises contacting a membrane fraction from nonneuronal cells transfected with and expressing DNA encoding a human, rat, or canine Y5 receptor, with the chemical compound under conditions suitable for activation of the Y5 receptor, and measuring the binding of GTPγS to the membrane fraction in the presence and in the absence of the chemical compound, a change in the binding of GTPγS in the presence of the chemical compound indication that the chemical compound activates the Y5 receptor, wherein such cells prior to being transfected with such DNA do not express the human, rat, or canine Y5 receptor, and wherein the human Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 6 (SEQ ID NO:

• 4) or that encoded by plasmid pcEXV-hY5 (ATCC Accession NO. 75943), the rat Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 4 (SEQ ID NO:
• 2) or that encoded by plasmid pcEXV-rY5 (ATCC Accession No. 75944);
• and the canine Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 24 (SEQ ID NO:
• 14) or that encoded by plasmid cY5-B011 (ATCC Accession No. 97587).

A process for determining whether a chemical compound specifically binds to and inhibits activation of a Y5 receptor, which comprises contacting nonneuronal cells transfected with and expressing DNA encoding a human, rat, or canine Y5 receptor, with both the chemical compound and a second chemical compound known to activate the Y5 receptor, and separately with only the second chemical compound, under conditions suitable for activation of the Y5 receptor, and measuring binding of GTPγS to the cells in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in GTPγS binding in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of a Y5 receptor, wherein such cells prior to being transfected with such DNA do not express the human, rat, or canine Y5 receptor, and wherein the human Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 6 (SEQ ID NO:

• 4) or that encoded by plasmid pcEXV-hY5 (ATCC Accession No. 75943);
• the rat Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 4 (SEQ ID NO:
• 2) or that encoded by plasmid pcEXV-rY5 (ATCC Accession No. 75944);
• and the canine Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 24 (SEQ ID NO:
• 14) or that encoded by plasmid cY5-B011 (ATCC Accession No. 97587).

A process for determining whether a chemical compound specifically binds to and inhibits activation of a Y5 receptor, which comprises contacting a membrane fraction from a cell extract of nonneuronal cells transfected with and expressing DNA encoding a human, rat, or canine Y5 receptor, with both the chemical compound and s second chemical compound known to activate the Y5 receptor, and separately with only the second chemical compound, and measuring binding of the GTPγS to the membrane fraction in the presence of only the second chemical compound and in the presence of both the chemical compound and the second chemical compound, a smaller change in GTPγS binding in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of a Y5 receptor, wherein such cells prior to being transtected with such SNA do not express the human, rat, or caninge Y5 receptor, and wherein the human Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 6 (SEQ ID NO:

• 4) or that encoded by plasmid pcEXV-hY5 (ATCC Accession No. 75943);
• the rat Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 4 (SEQ ID NO:
• 2) or that encoded by plasmid pcEXV-rY5 (ATCC Accession No. 75944);
• and the canine Y5 receptor has an amino acid sequence identical to the amino acid sequence shown in FIG. 24 (SEQ ID NO:
• 14) or that encoded by plasmid cY5-B011 (ATCC Accession No. 97587).